Pharmafile Logo
Pharmafocus logo
Advanced Search

SMC

Showing 15 posts of 37 posts found.

bms

SMC reverses decision on Opdivo in advanced skin cancer

August 8, 2016
Manufacturing and Production, Research and Development SMC, Scottish Medicines Consortium, melanoma, opdivo, skin cancer

The Scottish Medicines Consortium (SMC) has reversed an earlier decision for Bristol-Myers Squibb’s Opdivo (nivolumab) and has now approved recommended …

News
chemo-web

SMC recommends treatment for potentially fatal chemotherapy-related disease

June 16, 2016
Research and Development, Sales and Marketing Menarini, SMC, adneuric

The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …

News

Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco

May 10, 2016
Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation

The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX).  SMC did not recommend …

News
bms

BMS criticises Scottish regulator over Opdivo skin cancer ‘no’

March 7, 2016
Medical Communications, Research and Development Bristol-Myers Sqibb, NICE, SMC, melanoma, opdivo

Bristol-Myers Squibb says the Scottish Medicines Consortium’s (SMC) decision not to recommend its immunotherapy Opdivo (nivolumab) as a monotherapy for …

News
Jinarc

SMC approves first ever treatment for genetic kidney disease

January 12, 2016
Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

News
Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

News
afinitor_logo

Blow for Scottish women as SMC rejects Afinitor for advanced breast cancer

October 12, 2015
Sales and Marketing SMC, advanced breast cancer

The Scottish Medicines Consortium (SMC) has announced that it will not recommend Novartis’s Afinitor (everolimus) for use in advanced breast …

News
Celgene image

NICE rejects Otelza but SMC recommends it

June 11, 2015
Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla

Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …

News
NHS image

Scottish Medicines Consortium approves seven drugs

May 12, 2015
Sales and Marketing NHS, SMC, Scottish Medicines Consortium

The Scottish Medicines Consortium has accepted seven new medicines and indications for use on the NHS in Scotland. Two of …

News

Scottish reforms proven to work says SMC

March 4, 2015
Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish

The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …

News
AZ image

AstraZeneca diabetes drug approved for use in Scotland

November 11, 2014
Sales and Marketing Afinitor, AstraZeneca, Eylea, Onglyza, Perjeta, SMC, diabetes, type 2

The Scottish Medicines Consortium (SMC) has shown AstraZeneca’s Onglyza (saxagliptin) the green light to be used with insulin in patients …

News
Celgene image

Scottish Medicines Consortium disappoints Celgene

July 8, 2014
Sales and Marketing Celgene, SMC, Scottish Medicines Consortium, imnovid, myeloma

Celgene admitted it is ‘disappointed’ with the Scottish Medicines Consortium decision not to recommend blood cancer therapy Imnovid for patients …

News
gilead_-sciences

NICE rejection looms for Sovaldi

June 16, 2014
Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …

News
Sovaldi image

Sovaldi hurdles first drug pricing barrier

June 10, 2014
Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi

Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …

News

Scotland reforms will see drug access improve

February 3, 2014
Sales and Marketing PACE, SMC, Scotland, drugs, neil

Scotland is set to overhaul its medicines access system after complaints from charities and interest groups that patients have been …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025